MedTrace Logo

Alpha-Lipoic Acid in Mitigating Cisplatin-Induced Nephrotoxicity

NCT07564479 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2026-05-04

No results posted yet for this study

Summary

To assess the nephroprotective efficacy of Alpha-Lipoic Acid in preventing cisplatin-induced nephrotoxicity in oncology patients by monitoring renal function changes

Conditions

  • Cisplatin Nephrotoxicity
  • Nephrotoxicity

Interventions

DRUG

Alpha-Lipoic Acid (ALA)

The intervention under investigation is the administration of oral Alpha-Lipoic Acid (ALA) as an adjunct to standard cisplatin-based chemotherapy.

Sponsors & Collaborators

  • Minia University Hospital

    collaborator OTHER

  • Minia University

    lead OTHER

Principal Investigators

  • Ahmed Mostafa Abd-Elaziz · Department of Clinical Oncology, Faculty of Medicine, Minia University

  • Amal Kamal Hussein · Faculty of Pharmacy, Minia University

  • Eman Mohamed Sadek · Faculty of Pharmacy, Minia University

  • Asmaa Basem Mohammed · Faculty of Pharmacy, Minia University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-03-10
Primary Completion
2027-03-31
Completion
2027-06-30

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07564479 on ClinicalTrials.gov